Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Lung cancer e-learning for HCPs Topic: the evolving TROP2-directed ADC landscape in metastatic NSCLC + strategies to optimise the treatment experience Endorsed by ICAN, International Cancer Advocacy Network, Exon 20 Group, a multistakeholder organization & Biomarker Collaborative Supported by an Independent Educational Grant from AstraZeneca 📹

lung_connect's profile picture

LUNG CONNECT powered by COR2ED

1,052 subscribers

4,994,953 görüntüleme • 3 ay önce •via X (Twitter)

Bilim & TeknolojiEğitimSağlık & İyilik
LIVE

Anya Rossi• Live Now

Private livecam show

4 Yorum

Nathan Ndevweb profil fotoğrafı
Nathan Ndevweb2 ay önce

@WarOnCancer @Exon20Group @BiomarkerCo หัวข้อนี้น่าสนใจมากครับ ได้อัปเดตความก้าวหน้าการรักษาเลย

Namrata profil fotoğrafı
Namrata2 ay önce

@WarOnCancer @Exon20Group @BiomarkerCo Sponsored content on cancer treatment.

texcoco3d profil fotoğrafı
texcoco3d2 ay önce

@WarOnCancer @Exon20Group @BiomarkerCo Cuba has effective treatments for lung cancer despite america's decades-long economic war against it.

Haya profil fotoğrafı
Haya2 ay önce

@WarOnCancer @Exon20Group @BiomarkerCo اللي سهران صباح الخير على اللي يستاهل يصحى علشان خاطرك حد فاضي يشارك؟ اسمي ليلى 18 سنة بنوتة كيوت

Benzer Videolar

Revisiting key data from ELCC 2026 📺 Prof. Nicolas Girard joined us at ELCC 2026 to review oncogene-addicted NSCLC data from Beamion LUNG-1, SOHO-01, IELCART & OptiTROP-Lung03 Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Lung Cancer Europe , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer
4:30

Revisiting key data from ELCC 2026 📺 Prof. Nicolas Girard joined us at ELCC 2026 to review oncogene-addicted NSCLC data from Beamion LUNG-1, SOHO-01, IELCART & OptiTROP-Lung03 Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Lung Cancer Europe , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer

LUNG CONNECT powered by COR2ED

353,979 görüntüleme • 1 ay önce

Catch up on 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) data presented at ASCO 2026 Dr Herbert Loong, MBBS, FASCO & Dr Isabel Preeshagul joined us at ASCO 2026 to share their views on data emerging from the meeting 📺 Watch the video to get their expert insights on data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, and advances in HER2 testing Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer
4:40

Catch up on 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) data presented at ASCO 2026 Dr Herbert Loong, MBBS, FASCO & Dr Isabel Preeshagul joined us at ASCO 2026 to share their views on data emerging from the meeting 📺 Watch the video to get their expert insights on data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, and advances in HER2 testing Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer

LUNG CONNECT powered by COR2ED

841,885 görüntüleme • 2 ay önce

Pre-analytical phase challenges & biomarker testing in HER2+ metastatic breast cancer From Prof. Gary Tse, Dr Carlos Barrios, & Oncology Brothers Highlights in this video 📹 >> Endorsed by Biomarker Collaborative Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
5:46

Pre-analytical phase challenges & biomarker testing in HER2+ metastatic breast cancer From Prof. Gary Tse, Dr Carlos Barrios, & Oncology Brothers Highlights in this video 📹 >> Endorsed by Biomarker Collaborative Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.

BREAST CANCER CONNECT powered by COR2ED

20,493,435 görüntüleme • 3 ay önce

Personalised treatment in childhood cancer: A journey through 𝘕𝘛𝘙𝘒 fusion testing 📺Video for patients & families – please share with your network From Linet Menachery, patient advocate and mother of a child diagnosed with an 𝘕𝘛𝘙𝘒 fusion-positive pediatric cancer Endorsed by NTRKers, ICAN, International Cancer Advocacy Network & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer
4:51

Personalised treatment in childhood cancer: A journey through 𝘕𝘛𝘙𝘒 fusion testing 📺Video for patients & families – please share with your network From Linet Menachery, patient advocate and mother of a child diagnosed with an 𝘕𝘛𝘙𝘒 fusion-positive pediatric cancer Endorsed by NTRKers, ICAN, International Cancer Advocacy Network & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer

COR2ED

5,214,734 görüntüleme • 7 ay önce

Explore the testing and treatment journey in 𝑁𝑇𝑅𝐾 fusion-positive lung cancer How can we use molecular testing to enable personalised care? 📺Find out in this educational video from Dr Herbert Loong (Herbert Loong, MBBS, FASCO) Endorsed by ICAN, International Cancer Advocacy Network & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer
5:27

Explore the testing and treatment journey in 𝑁𝑇𝑅𝐾 fusion-positive lung cancer How can we use molecular testing to enable personalised care? 📺Find out in this educational video from Dr Herbert Loong (Herbert Loong, MBBS, FASCO) Endorsed by ICAN, International Cancer Advocacy Network & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer

LUNG CONNECT powered by COR2ED

1,829,894 görüntüleme • 3 ay önce

Managing ADC toxicities in HER2+ metastatic breast cancer - spotlight on nausea & vomiting Nausea/vomiting are common AEs associated with ADCs, particularly T-DXd, along with fatigue ILD, while less common, is an AE of special interest How can you manage N/V and more in clinical practice? Get step-by-step guidance from Dr Sara Tolaney Endorsed by ICAN, International Cancer Advocacy Network Supported by an Independent Educational Grant from AstraZeneca
6:39

Managing ADC toxicities in HER2+ metastatic breast cancer - spotlight on nausea & vomiting Nausea/vomiting are common AEs associated with ADCs, particularly T-DXd, along with fatigue ILD, while less common, is an AE of special interest How can you manage N/V and more in clinical practice? Get step-by-step guidance from Dr Sara Tolaney Endorsed by ICAN, International Cancer Advocacy Network Supported by an Independent Educational Grant from AstraZeneca

BREAST CANCER CONNECT powered by COR2ED

528,125 görüntüleme • 11 ay önce

Survey results published: Patient understanding of biomarker testing in non-small cell lung cancer (NSCLC) We surveyed patients & caregivers to assess awareness, knowledge & attitudes surrounding biomarker testing in NSCLC 📹 The results highlight gaps we can address to better support shared decision-making From medical experts Prof. Christian Rolfo , Prof. Fernando López-Ríos & Dr Rodrigo Paredes, MD , and made in collaboration with patient advocacy experts Dr. Amy C. Moore, Dr Anne-Marie Baird & Shani Shilo This programme is endorsed by LUNGevity Foundation, The Israeli Lung Cancer Foundation, NTRKers & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer
1:07

Survey results published: Patient understanding of biomarker testing in non-small cell lung cancer (NSCLC) We surveyed patients & caregivers to assess awareness, knowledge & attitudes surrounding biomarker testing in NSCLC 📹 The results highlight gaps we can address to better support shared decision-making From medical experts Prof. Christian Rolfo , Prof. Fernando López-Ríos & Dr Rodrigo Paredes, MD , and made in collaboration with patient advocacy experts Dr. Amy C. Moore, Dr Anne-Marie Baird & Shani Shilo This programme is endorsed by LUNGevity Foundation, The Israeli Lung Cancer Foundation, NTRKers & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer

LUNG CONNECT powered by COR2ED

2,703,909 görüntüleme • 3 ay önce

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of toxicities - Strategies to manage side effects 📹 Highlights video in this post Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by an Independent Educational Grant from Ipsen USA
4:31

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of toxicities - Strategies to manage side effects 📹 Highlights video in this post Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by an Independent Educational Grant from Ipsen USA

GI CONNECT powered by COR2ED

1,202,878 görüntüleme • 1 yıl önce

Update from ESMO 2025! >> Endometrial & ovarian cancer highlights 📺 Prof. Nicoletta Colombo reviews the latest data in gynecological cancers presented at the congress Could these developments impact clinical practice? Watch to find out! Endorsed by ICAN, International Cancer Advocacy Network This independent programme is supported by COR2ED
5:30

Update from ESMO 2025! >> Endometrial & ovarian cancer highlights 📺 Prof. Nicoletta Colombo reviews the latest data in gynecological cancers presented at the congress Could these developments impact clinical practice? Watch to find out! Endorsed by ICAN, International Cancer Advocacy Network This independent programme is supported by COR2ED

COR2ED

114,712 görüntüleme • 11 ay önce

ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC > N/V > Fatigue > Interstitial lung disease (rare but critical) From Prof. Shaheenah Dawood, Dr Sara Tolaney, Prof. Javier Cortes MD PhD, Carla Whitbread, Dr Grazyna Suchodolska & Prof. Giuseppe Curigliano Endorsed by the European Oncology Nursing Society (@cancernurseEU) and Europa Donna Supported by an Independent Educational Grant from AstraZeneca
3:41

ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC > N/V > Fatigue > Interstitial lung disease (rare but critical) From Prof. Shaheenah Dawood, Dr Sara Tolaney, Prof. Javier Cortes MD PhD, Carla Whitbread, Dr Grazyna Suchodolska & Prof. Giuseppe Curigliano Endorsed by the European Oncology Nursing Society (@cancernurseEU) and Europa Donna Supported by an Independent Educational Grant from AstraZeneca

BREAST CANCER CONNECT powered by COR2ED

7,264,225 görüntüleme • 7 ay önce

Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC) >> This is a rare and complex cancer that needs early diagnosis and intervention 📺 Watch the video from Meredith Cummins, INCA President-Elect, and CEO of NeuroEndocrine Cancer Australia, to find out: -Why urgency is needed in diagnosis & treatment -The potential of investigational treatments -Where to find support Endorsed by: INCA (NET Cancer Day). NeuroEndocrine Cancer Australia, Neuroendocrine Cancer UK #NotJustNECancer, Neuroendocrine Cancer Foundation, Neuroendocrine Cancer Research Foundation & Minkahz NETs Mission Supported by an Independent Educational Grant from Boehringer Ingelheim
5:45

Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC) >> This is a rare and complex cancer that needs early diagnosis and intervention 📺 Watch the video from Meredith Cummins, INCA President-Elect, and CEO of NeuroEndocrine Cancer Australia, to find out: -Why urgency is needed in diagnosis & treatment -The potential of investigational treatments -Where to find support Endorsed by: INCA (NET Cancer Day). NeuroEndocrine Cancer Australia, Neuroendocrine Cancer UK #NotJustNECancer, Neuroendocrine Cancer Foundation, Neuroendocrine Cancer Research Foundation & Minkahz NETs Mission Supported by an Independent Educational Grant from Boehringer Ingelheim

COR2ED

757,945 görüntüleme • 9 ay önce

EP-NEC: What do you need to know about diagnosis, treatment, and support? ~ A video podcast discussion ~ Unlike most NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers with, currently, a poor prognosis Medical Oncologist Dr Aman Chauhan & Neuroendocrine Patient Advocate Susan Meckler-Plummer, RN, address the key factors in managing this disease 📹 Highlights in this post Endorsed by Minkahz NETs Mission, Neuroendocrine Cancer UK #NotJustNECancer. Neuroendocrine Cancer Foundation and Neuroendocrine Cancer Research Foundation For more information or support, please speak with an HCP or reach out to a local patient advocacy group in your country or region Supported by an Independent Educational Grant from Boehringer Ingelheim
5:36

EP-NEC: What do you need to know about diagnosis, treatment, and support? ~ A video podcast discussion ~ Unlike most NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers with, currently, a poor prognosis Medical Oncologist Dr Aman Chauhan & Neuroendocrine Patient Advocate Susan Meckler-Plummer, RN, address the key factors in managing this disease 📹 Highlights in this post Endorsed by Minkahz NETs Mission, Neuroendocrine Cancer UK #NotJustNECancer. Neuroendocrine Cancer Foundation and Neuroendocrine Cancer Research Foundation For more information or support, please speak with an HCP or reach out to a local patient advocacy group in your country or region Supported by an Independent Educational Grant from Boehringer Ingelheim

NET CONNECT powered by COR2ED

1,568,210 görüntüleme • 4 ay önce

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success Part 1 of the highlights video in this post ~ Endorsed by Urobel & ZERO Prostate Cancer Supported by an Independent Educational Grant from AstraZeneca
5:33

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success Part 1 of the highlights video in this post ~ Endorsed by Urobel & ZERO Prostate Cancer Supported by an Independent Educational Grant from AstraZeneca

GU CONNECT powered by COR2ED

164,512 görüntüleme • 8 ay önce

🧬 What do HCPs need to know about current treatment options for advanced/recurrent EndometrialCancer? An animated MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to personalised therapies driven by molecular profiling. This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.
7:36

🧬 What do HCPs need to know about current treatment options for advanced/recurrent EndometrialCancer? An animated MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to personalised therapies driven by molecular profiling. This educational programme is sponsored by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.

OBSTETRICS & GYNECOLOGY CONNECT powered by COR2ED

240,514 görüntüleme • 1 yıl önce

EP-NEC = distinct, aggressive subtype of neuroendocrine cancer Often has late diagnosis, frequent mis-categorisation, and mis-understanding Complexity & burden of EP-NEC increased by delays in diagnosis/pt confusion/inconsistent Tx pathways/limited specialist access How can pts thrive after EP-NEC diagnosis? 📺 Watch the video to find out From Jessica Thomas, Director of Patient Education at the Neuroendocrine Tumor Research Foundation Endorsed by Neuroendocrine Cancer Research Foundation & Minkahz NETs Mission Supported by an Independent Educational Grant from Boehringer Ingelheim
4:51

EP-NEC = distinct, aggressive subtype of neuroendocrine cancer Often has late diagnosis, frequent mis-categorisation, and mis-understanding Complexity & burden of EP-NEC increased by delays in diagnosis/pt confusion/inconsistent Tx pathways/limited specialist access How can pts thrive after EP-NEC diagnosis? 📺 Watch the video to find out From Jessica Thomas, Director of Patient Education at the Neuroendocrine Tumor Research Foundation Endorsed by Neuroendocrine Cancer Research Foundation & Minkahz NETs Mission Supported by an Independent Educational Grant from Boehringer Ingelheim

NET CONNECT powered by COR2ED

824,857 görüntüleme • 4 ay önce

COVID vaccines linked to a 27% INCREASE in overall cancer risk, South Korean study finds. “There’s a one in a thousand chance that this result arose by chance,” Dr. John Campbell noted. Children’s Health Defense reports: The study used data from 2021-2023 for over 8.4 million people in South Korea’s National Health Insurance Service database. The sample was split into two groups based on vaccination status. The vaccinated sample was further split into booster and non-booster groups. Researchers tracked the patients for one year. The vaccinated group was tracked following vaccination. The results showed a statistically significant higher risk of cancer in the vaccinated group, including: Overall cancer: 27% higher risk Breast cancer: 20% higher risk Colorectal cancer: 28% higher risk Gastric cancer: 34% higher risk Lung cancer: 53% higher risk Prostate cancer: 69% higher risk Thyroid cancer: 35% higher risk
1:19

COVID vaccines linked to a 27% INCREASE in overall cancer risk, South Korean study finds. “There’s a one in a thousand chance that this result arose by chance,” Dr. John Campbell noted. Children’s Health Defense reports: The study used data from 2021-2023 for over 8.4 million people in South Korea’s National Health Insurance Service database. The sample was split into two groups based on vaccination status. The vaccinated sample was further split into booster and non-booster groups. Researchers tracked the patients for one year. The vaccinated group was tracked following vaccination. The results showed a statistically significant higher risk of cancer in the vaccinated group, including: Overall cancer: 27% higher risk Breast cancer: 20% higher risk Colorectal cancer: 28% higher risk Gastric cancer: 34% higher risk Lung cancer: 53% higher risk Prostate cancer: 69% higher risk Thyroid cancer: 35% higher risk

The Vigilant Fox 🦊

934,237 görüntüleme • 1 yıl önce